All Topics
All Topics
Technology
Technology
AI
AI
Business
Business
Entertainment
Entertainment
News
News
Programming
Programming
Science
Science
Design
Design
Environment
Environment
Finance
Finance
Crypto
Crypto
Politics
Politics
Sports
Sports
Education
Education
Gaming
Gaming
Art
Art
Music
Music
Health
Health
Security
Security
Books
Books
Food
Food
Travel
Travel
Personal
Personal
Bluesky
Twitter
First reported by The Independent
Daily weight loss pill available in UK pharmacies from today

FDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirements

By

Elena Vega

3h ago· 5 min readenNews

Summary

The FDA approved Foundayo (orforglipron), a new once-daily oral GLP-1 weight loss pill by Eli Lilly, on April 1, 2026. Unlike other oral GLP-1 drugs such as Wegovy's oral semaglutide (which requires morning fasting), Foundayo can be taken at any time of day with or without food or any beverage, with no timing restrictions. The article explains how Foundayo works, its efficacy (average 12.4% weight loss), side effects, and how it compares to existing GLP-1 treatments.

Source

Twitter / XFDA Approves Foundayo (orforglipron): The First Oral GLP-1 Weight Loss Pill Without Fasting Requirementsmedicaldaily.com

Key quotes

· 3 pulled
Foundayo (orforglipron), developed by Eli Lilly and approved by the FDA on April 1, 2026, is a once-daily oral GLP-1 receptor agonist that can be taken at any time of day — with food, without food, or with any beverage — with no timing restrictions whatsoever.
The Wegovy pill (oral semaglutide), which was approved in December 2025, must be taken with a sip of water in the morning on an empty stomach.
Average weight loss: 12.4%.
Snippet from the RSS feed
FDA approved Foundayo (orforglipron) on April 1, 2026 — the only oral GLP-1 pill for weight loss you can take any time of day without fasting. Average weight loss: 12.4%. Here's the breakdown.

You might also wanna read

Comments

Sign in to join the conversation.

No comments yet. Be the first.